- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
GSK Forced to Halt Phase 3 Trial of the NSCLC Drug MAGE-A3
GlaxoSmithKline has been forced to halt a Phase III trial assessing its MAGE-A3 cancer immunotherapeutic in patients with non-small cell lung cancer (NSCLC).
GlaxoSmithKline has been forced to halt a Phase III trial assessing its MAGE-A3 cancer immunotherapeutic in patients with non-small cell lung cancer (NSCLC).
High hopes for the experimental immunotherapy - designed to help patients stave off the return of the disease after treatment - came after it emerged that researchers would not be able to identify a subset of patients who may benefit from its therapy, hot on the heels of other disappointing data.
Last month it was revealed that the MAGRIT trial failed to meet its primary and secondary endpoints after the treatment failed to significantly extend disease-free survival (DFS) when compared to placebo, in either the overall MAGE-A3 (a specific tumour antigen) positive population or in MAGE-A3-positive patients who did not receive chemotherapy.
Read more here: http://bit.ly/1mKib9J
Source: PharmaTimes online
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
